Corbus Pharmaceuticals (CRBP) PT Raised to $36 at Cantor Fitzgerald as Lenabasum's Gain, Following Tocilizumab's Loss
Tweet Send to a Friend
Cantor Fitzgerald analyst Elemer Piros raised the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $36.00 (from $32.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
